Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 21 Jul 2018
At a glance
- Drugs Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 16 Jul 2018 Planned primary completion date changed from 1 Jul 2026 to 15 Mar 2020.
- 17 Jul 2017 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2016 Planned number of patients changed from 224 to 180.